Mural Oncology Files Definitive Additional Materials

TL;DR

Mural Oncology filed proxy docs, check for updates.

AI Summary

Mural Oncology plc filed a DEFA14A on October 17, 2025, indicating it is a definitive additional material filing. The company, previously known as Mural Oncology Ltd and Pistachiovale Ltd, is incorporated in L2 and has its fiscal year end on December 31. Its business address is in Dublin, Ireland.

Why It Matters

This filing provides important updates and materials related to shareholder matters for Mural Oncology plc, which could influence investor decisions.

Risk Assessment

Risk Level: low — This filing is a standard proxy statement amendment and does not inherently indicate new risks.

Key Players & Entities

• Mural Oncology plc (company) — Registrant
• Mural Oncology Ltd (company) — Former company name
• Pistachiovale Ltd (company) — Former company name
• 20251017 (date) — Filing date

FAQ

Filing Documents

• d40331ddefa14a.htm (DEFA14A) — 28KB
• g40331g1017094014445.jpg (GRAPHIC) — 4KB
• 0001193125-25-242506.txt ( ) — 35KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under Rule 14a-12 Mural Oncology plc (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee previously paid with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. MURAL ONCOLOGY PLC Ten Earlsfort Terrace Dublin 2 D02 T380 Ireland **** IMPORTANT REMINDER TO VOTE YOUR SHARES AT BOTH SPECIAL MEETINGS**** Dear Mural Shareholder, This letter is a reminder that a Scheme Meeting and an Extraordinary General Meeting of Mural Oncology plc ("Mural") will be held on Friday, October 24, 2025 at the offices of Arthur Cox LLP at Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland. The Scheme Meeting will begin at 10:30 a.m. Irish local time and the Extraordinary General Meeting will begin at 10:45 a.m. Irish local time (or, if the Scheme Meeting has not concluded by 10:45 a.m. Irish local time, as soon as possible after the conclusion of the Scheme Meeting). Because the Scheme Meeting and the Extraordinary General Meeting are two, separate special meetings of shareholders, Mural shareholders are being asked to vote twice. That means a Mural Shareholder who wishes to vote by mailing back a proxy card must complete and mail two proxy cards – the proxy card for the Scheme Meeting and the proxy card for the Extraordinary General Meeting – to ensure the shareholder's votes for both meetings are recorded. Similarly, a Mural Shareholder, who wishes to vote by telephone or over the Internet must vote following the instructions on both the proxy card for the Scheme Meeting and the proxy card for the Extraordinary General Meeting to ensure the shareholder's votes for both meetings are recorded. YOUR VOTES ARE IMPORTANT! Please be sure to vote on the proposals for consideration at both the Scheme Meeting and the Extraordinary General Meeting no later than 11:59 p.m. Irish local time (6:59 p.m. U.S. Eastern Time) on October 23, 2025 to be counted at the special meetings . If you have already submitted your votes for both special meetings, we would like to thank you for your votes. The proxy materials previously sent by Mural to you on or about September 23, 2025 contain important information regarding the proposals that you and other shareholders are being asked to consider. Mural strongly encourages each shareholder to read this letter and the materials previously circulated carefully and in their entirety. If you have any questions regarding the proposals, or need assistance with voting, you may reach Mural's proxy solicitor, toll free at 800-322-2885 or by email at proxy@mackenziepartners.com. We appreciate your ongoing support for Mural. Sincerely, /s/ Caroline Loew Caroline Loew, Ph.D. Chief Executive Officer Tel: +353 1 920 1000 Email: ir@muraloncology.com IMPORTANT NOTICES No Offer or Solicitation This communication is for information purposes only and is not intended to, and does not, constitute or form part of any recommendation or offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities or the solicitation of any proxy, vote or approval in any jurisdiction, whether pursuant to this communication or otherwise. The distribution of this communication in jurisdictions outside Ireland or the United States may be restricted by law and therefore persons into whose possession this communication comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction. The Acquisition will be made solely by means of a Proxy Statement distributed to Mural's shareholders and containing a description of the Scheme (the "Scheme") and the full terms and conditions of the Acquisition, including details of how Mural Shareholders may vote in respect of the Acquisition. Any decision in respect of, or other response to, the Acquisition, should be made only on the basis of the information contained in the Proxy Statement and the Scheme. Capitalized terms used but not defined herein are as defined in the Proxy Statement. This communication does not constitute a prospectus or a prospectus equivalent document. Important Additional Information and Where to Find It In connection with the Acquisition, Mural has filed with the Secu

View Full Filing

View this DEFA14A filing on SEC EDGAR